Modeling the effect of enzyme replacement therapy on life-threatening complications in patients with Fabry disease

• Hauptverfasser: V. I. Ignatyeva (Verfasst von), S. V. Moiseev (Verfasst von), N. M. Bulanov (Verfasst von), E. A. Karovajkina (Verfasst von), A S. Moiseev (Verfasst von)
• Format: Buch
• Veröffentlicht: IRBIS LLC, 2019-01-01T00:00:00Z.
• Schlagworte: article
• Online-Zugang: Connect to this object online.

Fabry disease (FD) is a severe lysosome storage disease caused by congenital deficiency of the enzyme α-galactosidase A and characterized by the risk of renal failure combined with cardiovascular and CNS complications. According to the currently available information, the early start of enzyme repla...